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Introduction 
Nowadays, the number of new fixed-dose combinations (FDCs) is rising 
significantly.  FDC is a medicine that includes two or more active 
pharmaceutical ingredients (APIs) combined in a single dasage 
form. Therefore, compatibility determination between APIs in fixed-dose 
combinations is an indispensable step in the elaboration. To investigate 
the compatibility of the components of a formulation, techniques, such as 
X-ray diffraction, FT-IR spectroscopy, high-performance liquid 
chromatography (HPLC) and thermal analysis (especially differential 
scanning calorimetry -  DSC) are used. The present study is based HPLC 
High-performance liquid chromatography provides information on 
possible interactions between APIs and their related interaction products.  
Purpose 
The purpose of the present study was to investigate the compatibility of 
potassium orotate in combination with spironolactone by the HPLC 
method.  
 Material and methods 
The detection was carried out using Liquid Chromatograph Agilent 1100 
equipped with autosampler, UV-VIS detector, applying mobile phase, 
which consists of acetonitrile and phosphate buffer solution (pH=4.0) 
ratio in 1:49 and 1:1, at flow rates 1 and 1.5 mL/min, injection volume 
20 μL. The study was made on a RP-18 reversed column (250mm long 
by 4 mm internal diameter, particle size 5μm) and at an isocratic elution 
method. The APIs (potassium orotate and spironolactone) were provided 




Due to developed method both separation and simultaneous qualitative 
and quantitative determination of APIs in the mechanical mixture were 
carried out, using HPLC. Spironolactone: retention time 6.9 min, 
concentration 98.1% (±0.21); potassium orotate: retention time 3.06 
min, concentration 91.67% (±0.15). There were just well-separated 




There is compatibility between APIs. Further studies will be performed 
by other methods (DSC, FT-IF Spectrometry) to confirm the obtained 
result. 
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Chromatograms of mixture ( potassium orotate with spironolactone) at 278 nm 
and 240nm simultaneously mobile phase N1 and mobile phase N2. 
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